Scientists discovered a new way to protect memory in Alzheimer's by targeting the blood-brain barrier instead of amyloid ...

HSV-1 infection may be linked to the risk for Alzheimer’s disease, but antiviral treatment may be protective, a large ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

The early use of Blarcamesine shows promise in treating Alzheimer's, boosting Anavex's potential. Click here to read an analysis of AVXL stock now.

Treating cold sores with anti-viral medicines could help slash the risk of Alzheimer’s disease, research suggests. Previous ...

The FDA cleared the test for early detection of amyloid plaques associated with Alzheimer’s in people aged 55 years and older ...

TREATING cold sores with anti-viral medicines could slash the risk of Alzheimer’s disease by 17 per cent, research suggests. Previous studies have found that the herpes simplex virus – ...

Researchers have found that the herpes virus, which causes cold sores, increases Alzheimer’s risk by as much as 80% by ...

The US FDA has approved the first blood test to detect Alzheimer's disease in its early stages. This advancement promises ...

More info There has never been “such positivity” about treatments for Alzheimer’s, and big changes will ... was recently approved by the European Medicines Agency (EMA).

Proposed intravenous maintenance dosing application to reduce lecanemab infusion frequency from every two weeks to every four weeks for eligible adult UK patients after initial 18 months of treatment ...